Astellas taps seasoned CMO amid shift to oncology; Doug Manion steps into a new Arena following $6.7B buyout

Bernhardt Zeiher

As Bernhardt Zeiher retires from Astellas’ chief medical officer position, the selection of his successor says a lot about the changes he’s seen at the company over his 12-year tenure.

Tadaaki Taniguchi, the new CMO, is a surgeon in oncology by training who’s led development for Merck, Bristol Myers Squibb and AstraZeneca in Japan before moving to the US, where he will be based. His most recent role at AstraZeneca was SVP, head of oncology business unit Asia strategy.

Looking back on his time, Zeiher told Endpoints News that he believes the successes his group — spanning almost 2,700 people — has had with the current pipeline sets the company up for the next wave of cancer therapies, be it bifunctional antibodies, cell therapies or oncolytic viruses. On top of notching label expansions for the Pfizer-partnered prostate Xtandi, in…
Click here to view original post